GB Sciences, Inc. (18C.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR

Add to watchlist

0.0050

0.0000

(0.00%)

As of 08:16AM CEST. Market open.

Loading interactive chart...

ACCESSWIRE
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)
Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences' cannabinoid-based medicine for the treatment of Parkinson's disease.LAS VEGAS, NV / ACCESSWIRE / December 14, 2023 / Gb Sciences, Inc. (OTCQB:GBLX), ...
ACCESSWIRE
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model.